

To,
BSE Limited,
Floor 25, P J Towers,
Dalal Street, Mumbai – 400001
Script Code: 543963

Subject: Outcome of the Board Meeting and Submission of the Unaudited Standalone Financial Results for the Half year ended on 30th September, 2024

Ref: Regulation 30, 33 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with corresponding circulars and notifications issued thereunder.

Dear Sir/Madam,

This is to inform you that, the Board of Directors at their meeting held on today i.e. 30th October, 2024 at 11:15 A.M. and Concluded at 11:30 A.M. at 5th Floor, Sakar 4, Opp. MJ Library, Ashram Road, Paldi, Ellisbridge, Ahmedabad-380006, Gujarat, India, interalia discussed and considered the following matters:

1. Approval of Standalone Unaudited Financial Result for the Half Year ended on 30th September, 2024 as per Regulation 33 of the SEBI (LODR) Regulations, 2015 along with Limited Review report;

Kindly take the above on record and oblige.

Thanking You.

FOR, SHELTER PHARMA LIMITED

MUSTAQIM NISARAHMED SABUGAR
MANAGING DIRECTOR
DIN: 01456841

Date: 30th October, 2024

Place: Ahmedabad

CC:

1. Financials

Shelter Pharma Limited

Regd. Office & Works: Shelternagar, Opp. Bus Station, Himatnagar-383001 Gujarat, India.

Corporate Office: 5th Floor, Sakar 4, Opp. MJ Library, Ashram Road, Paldi, Ellisbridge, Ahmedabad-380006, Gujarat, India.

Email: info@shelter.co.in **Phone:** +91 2772 240108/246995

CIN: L24233GJ2007PLC051956



Mendajiwala & Co.

Chartered Accountant

Ref. No. :

Date :

Independent Auditor's Review Report on the Unaudited Standalone Financial Results of the SHELTER PHARMA LIMITED for the half year ended on September 30, 2024 under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.

To,
The Board of Directors of
Shelter Pharma Limited

We have reviewed the accompanying statement of standalone unaudited financial results of **SHELTER PHARMA LIMITED (the "Company")** (PAN: AALCS3158D) for the half year ended on 30.09.2024 (the "Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations").

This Statement, which is the responsibility of the Company's management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Accounting Standard 25 'Interim Financial Reporting' ('AS 25'), prescribed under Section 133 of the Companies Act, 2013, as amended, read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with regulation 33 of the SEBI (Listing obligations and Disclosure Requirements) regulations, 2015, as amended (the SEBI Listing Regulations'). Our responsibility is to issue a report on the Statement based on our review. Our responsibility is to express a conclusion on the statement based on our review.

Scope of our review

We conducted our review of the statement in accordance with the Standards on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by ICAI. A review of statement consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid accounting standards and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Our conclusion is not modified in respect of these matters.

For, Mendajiwala & Co.

Chartered Accountants

(Firm Reg. No.: 0135065W)

MOHAMMEDSOELN Mendajiwala
Proprietor

Membership No.: 146324

UDIN: 24146324BKAAYK1472

Date: October 30, 2024

Place: Ahmedabad



SHELTER PHARMA LIMITED



CIN NO. : L24233GJ2007PLC051956

Standalone Statement of Assets and Liabilities as on September 30,2024

(Rs.In Lakhs)

Particulars	For the period ended on 30.09.2024	For the year ended on 31.03.2024
	(Un Audited)	(Audited)
I. EQUITY AND LIABILITIES		
(1) Shareholder's Funds		
(a) Share Capital	1,155.98	1,155.98
(b) Reserves and Surplus	2,775.59	2,425.60
(2) Non-Current Liabilities		
(a) Long-Term Borrowings	101.42	57.32
(b) Deferred Tax Liabilities (Net)		
(c) Other Long Term liabilities		
(d) Long term Provisions	5.48	5.10
(3) Current Liabilities		
(a) Short-Term Borrowings	10.33	0.41
(b) 1. Trade Payables - others	49.84	70.12
2. Trade Payables - MSME	0.23	1.28
(c) Other Current Liabilities	6.23	6.16
(d) Short-Term Provisions	192.78	69.52
Total Equity & Liabilities	4,297.87	3,791.48
II. ASSETS		
(1) Non-Current Assets		
(a) Plant, Porperty & Equipments and Intangible Assets		
(i) Plant, Porperty & Equipments	435.94	357.07
(ii) Intangible Assets	0.86	0.88
(b) Non-current Investments	67.63	67.63
(c) Deferred tax assets (net)	3.17	3.56
(d) Long term loans and advances	442.37	390.46
(e) Other Non-Current Assets		
(2) Current Assets		
(a) Current investments		
(b) Inventories	989.12	992.90
(c) Trade receivables	947.74	885.01
(d) Cash and cash Equivalents	599.77	503.97
(e) Short-term loans and advances	620.06	389.40
(f) Other Current Assets	191.21	200.59
Total Assets	4,297.87	3,791.48

As our Report of even date.

For Shelter Pharma Limited

For Mendajiwala & Co.


Chartered Accountants

Mohammed Soel N Mendajiwala

Proprietor


Membership No. :146324

Firm Reg. No.: 0135065W



Mustaqim N Sabugar
Chairmain & Managing Director

DIN: 01456841



Shakil N Sabugar
Whole Time Director

DIN: 01474868

Place: Ahmedabad

Date: 30/10/2024

SHELTER PHARMA LIMITED

CIN NO.: L24233GJ2007PLC051956




Statement of Standalone UnAudited Financial Result for the half year ended September,30 2024

(Rs.In Lakhs Except Shares Price)

Sr. No	Particulars	Half Year / Period ended			Year / Period ended		Year Ended
		30.09.2024	31.03.2024	30.09.2023	30.09.2024	30.09.2023	31.03.2024
		(Un-Audited)	(Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Audited)
Income							
I	Revenue from operations	2,405.67	2,071.08	1,931.20	2,405.67	1,931.20	4,002.29
II	Other Income	0.21	0.25	0.13	0.21	0.13	0.39
III	Total Income (I +II)	2,405.88	2,071.34	1,931.34	2,405.88	1,931.34	4,002.67
Expenses							
IV	(a) Cost of Material Consumed	1,776.98	1,459.56	1,425.81	1,776.98	1,425.81	2,885.38
	(b) Purchases of Stock-in-Trade						
	(c) Changes in inventories of finished goods work-in-progress and Stock-in-Trade	2.57	17.58	-10.50	2.57	-10.50	7.08
	(d) Employee Benefit Expense	62.33	48.14	38.47	62.33	38.47	86.61
	(e) Finance Cost	6.95		4.66	6.95	4.66	4.66
	(f) Depreciation & Amortised Expense	9.79	12.62	11.98	9.79	11.98	24.60
	(g) Other Expenses	74.15	105.03	48.92	74.15	48.92	153.95
	Total Expenses	1,932.77	1,642.93	1,519.34	1,932.77	1,519.34	3,162.28
V	Profit before exceptional and extraordinary items and tax (III - IV)	473.11	428.40	411.99	473.11	411.99	840.40
VI	Exceptional Items						
	Prior Period Items						
VII	Profit before extraordinary items and tax (V - VI)	473.11	428.40	411.99	473.11	411.99	840.40
VIII	CSR Provision		12.14				12.14
IX	Profit before tax (VII - VIII)	473.11	416.27	411.99	473.11	411.99	828.26
X	Tax expense:						
	(1) Current tax	119.08	104.77	103.70	119.08	103.70	208.47
	(2) Deferred tax	0.39	-3.56	-1.85	0.39	-1.85	-3.56
	(3) Prior Period tax		3.33				3.33
	(4) Less : TDS						
XI	Profit/(Loss) for the period from continuing operations (IX - X)	353.64	311.72	310.14	353.64	310.14	620.02
XII	Profit/(loss) from discontinuing operations						
XIII	Tax expense of discounting operations						
XIV	Profit/(Loss) from Discontinuing operations (after tax) (XII - XIII)						
XIII	Profit/(Loss) for the period (XI + XIV)	353.64	311.72	310.14	353.64	310.14	620.02
XVI	Earning per equity share of Rs.10 each						
	(1) Basic	3.06	2.70	2.68	3.06	2.68	5.36
	(2) Diluted	3.06	2.70	2.68	3.06	2.68	5.36

As our Report of even date.
For Mendajiwala & Co.
Chartered Accountants

Mohammed Soel N Mendajiwala
Proprietor
Membership No. :146324
Firm Reg. No.: 0135065W



For Shelter Pharma Limited

Mustaqim N Sabugar
Mustaqim N Sabugar
Chairman & Managing Director
DIN: 01456841

Shakil N Sabugar
Shakil N Sabugar
Whole Time Director
DIN: 01474868

Place: Ahmedabad
Date: 30/10/2024

SHELTER PHARMA LIMITED

CIN NO.: L24233GJ2007PLC051956



Standalone Cash Flow Statement for the period ended September 30, 2024

(Rs.In Lakhs)

Particulars		For the period ended on 30.09.2024	For the year ended on 31.03.2024
		(Un Audited)	(Audited)
A) CASH FLOW FROM OPERATING ACTIVITIES			
Net Profit / (Loss) Before Tax & Extra Ordinary Items:		473.11	840.40
Adjustments For:			
Depreciation & Amortization Expense		9.79	24.60
Provision for Gratuity			
Bad debt		15.00	30.00
Deferred tax exp / income		(0.39)	3.56
Finance Cost		(6.95)	
Non-operating income (Intrest Received, etc)			(0.39)
Operating Profit Before Working Capital Changes	i.	490.56	898.17
Adjustments For:			
(Increase)/ Decrease in Inventories		3.78	-206.55
(Increase)/ Decrease in Trade Receivables		-62.72	-65.54
(Increase)/ Decrease in Short Term Loans & Advances		-230.66	-389.30
(Increase)/ Decrease in Other Current Assets		9.38	12.13
Increase/ (Decrease) in Trade Payable		-21.34	24.66
Increase/ (Decrease) Other Current Liabilities		0.07	-256.21
Increase/ (Decrease) Short Term Borrowings		9.92	-130.01
Increase/ (Decrease) Short term provision		123.26	84.59
	ii.	-168.31	-926.24
Cash Generated From Operations	i+ii	137.34	156.96
Income Tax Paid			
Net Cash From Operating Activities	(A)	184.92	(185.02)
B) CASH FLOW FROM INVESTING ACTIVITIES			
Purchase of Fixed Assets		-88.64	-85.19
Purchase of Shares & Funds		-	-
Repayment of Long Term Loans & Advances		(51.91)	-369.34
Intrest Received			0.13
Net Cash From Investing Activities	(B)	(140.56)	(454.40)
C) CASH FLOW FINANCING ACTIVITIES			
Proceeds from issuance of Share Capital		-	1,091.23
Increase / (Decrease) in Long term Borrowings		44.11	9.32
Longtern Provision		0.38	
Finance Cost		6.95	
Net Cash From Financing Activities	(C)	51.44	1,100.55
Increase in Cash and Cash Equivalents	(D)	95.80	461.13
(A)+(B)+(C)			
Cash and Cash Equivalents at the Beginning of the Year	(E)	503.97	42.85
Cash and Cash Equivalents at the End of the Year	(D) +(E)	599.77	503.98
Components of Cash and Cash Equivalents:			
Cash on Hand		81.14	84.75
Other Bank Balances		518.63	419.22
Total		599.77	503.98

Notes:

- 1) The cash flow statement has been prepared in accordance with the requirement of Companies Act 2013.
- 2) Figures in brackets indicate Cash Outflow

For Mendajiwala & Co.
Chartered Accountants



Mohammed Soel N Mendajiwala
Proprietor

Membership No. :146324
Firm Reg. No.: 0135065W

For Shelter Pharma Limited

Mustaqim N Sabugar
Chairman & Managing Director
DIN: 01456841



Shakil N Sabugar
Whole Time Director
DIN: 01474868

Place: Ahmedabad
Date: 30/10/2024